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ARTICLE
Hypoxia-inducible factor-1a restricts the anabolic actions of
parathyroid hormone
Julie L Frey1, David P Stonko1, Marie-Claude Faugere2 and Ryan C Riddle1,3
The hypoxia inducible factors (Hifs) are evolutionarily conserved transcriptional factors that control
homeostatic responses to low oxygen. In developing bone, Hif-1 generated signals induce angiogenesis
necessary for osteoblast specification, but in mature bone, loss of Hif-1 in osteoblasts resulted in a more rapid
accumulation of bone. These findings suggested thatHif-1 exerts distinct developmental functions and acts as a
negative regulator of bone formation. To investigate the function of Hif-1a in osteoanabolic signaling, we
assessed the effect of Hif-1a loss-of-function on bone formation in response to intermittent parathyroid
hormone (PTH). Mice lacking Hif-1a in osteoblasts and osteocytes form more bone in response to PTH, likely
through a larger increase in osteoblast activity and increased sensitivity to the hormone. Consistent with this
effect, exposure of primarymouse osteoblasts to PTH resulted in the rapid induction ofHif-1aprotein levels via
a post-transcriptional mechanism. The enhanced anabolic response appears to result from the removal of
Hif-1a-mediated suppression of b-catenin transcriptional activity. Together, these data indicate that Hif-1a
functions in themature skeleton to restrict osteoanabolic signaling. The availability of pharmacological agents
that reduceHif-1a function suggests the value in further exploration of this pathway to optimize the therapeutic
benefits of PTH.
Bone Research (2014) 2, 14005; doi:10.1038/boneres.2014.5; Published online 13 May 2014
INTRODUCTION
Parathyroid hormone (PTH), an 84-amino-acid polypep-
tide, is an essential regulator of mineral homeostasis and
bone remodeling. Released by the chief cells of the para-
thyroid gland in response to deviations in serum calcium
levels, PTH primarily acts on kidney and bone to increase
calcium reabsorption and liberate calcium from bone
matrix, respectively.1 Additionally, intermittent PTH admin-
istration is recognized for its anabolic effects in bone, and
the first 34 amino acids of the hormone form the basis for
the only Food and Drug Administration-approved ana-
bolic agent to treat osteoporosis.2–4
The anabolic actions of PTH have been extensively
studied in laboratory rodent models.5 Through its actions
on the PTH receptor,6 expressed by osteoblasts and osteo-
cytes, histological analyses suggest that intermittent PTH
increases bone acquisition by increasing the number of
bone-forming osteoblasts.7–9 More recent molecular ana-
lyses have attempted to identify signaling mechanisms
and components that allow PTH to reduce bone cell
apoptosis,9 stimulate progenitor cell recruitment10 and
activate formerly quiescent bone lining cells.11 In addition
to the activation of cyclic AMP (cAMP) and protein kinase
A signaling,12 components of the insulin-like growth factor
pathway,13–15 the transforming growth factor-b path-
way10,16 and Wnt/b-catenin signaling17–18 have all been
demonstrated to be required for the full osteo-anabolic
response to PTH. The identification of factors or signaling
mechanisms that inhibit bone formation after PTH admin-
istration has been less common,19–20 but examining such
mechanisms could facilitate the development of strat-
egies to increase the therapeutic efficacy of intermittent
PTH.
Hypoxia inducible factor-1 (Hif-1) is most widely recog-
nized for its role in the cellular response to molecular
oxygen levels.21–22 A basic helix–loop–helix transcription
factor, the activity and cellular abundanceof Hif-1 is regu-
lated by an oxygen-dependent proteolysis mechanism.
At normal oxygen tensions, the a-subunit of the protein
(Hif-1a) undergoes prolyl hydroxylation, which initiates
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recognition by the von Hippel–Lindau (Vhl) tumor sup-
pressorprotein, acomponentof theE3ubiquitin ligase that
targets Hif-1a for proteasomal degradation.When oxygen
tensions fall below 5%, prolyl hydroxylation is inhibited; Hif-
1a accumulates and translocates to the nucleus where it
formsadimerwith theHif-1b subunit. In vitro studies suggest
that Hif-1 regulates the expression of several hundred
genes involved in angiogenic andmetabolic responses,21
and utilizes both direct promoter binding23 as well as indir-
ect mechanisms to alter gene expression.24
Within bone, Hif-1 exerts distinct developmental func-
tions. In developing bone, Hif-1 generated signals are
required for angiogenesis, which appears to be necessary
for initial specification of bone-forming osteoblasts.
Consistent with this idea, mice lacking Hif-1a in osteoblasts
and osteocytes develop poorly vascularized bones with
reduced cortical and trabecular bone volume, while Hif
overexpression results in highly vascularized and dense
bone.25–26 As Hif-1a mutant mice mature, a second inhib-
itory function emerges such that Hif-1 acts as a negative
regulator of bone formation. In this regard, cortical and
trabecular bone volume normalize with age and Hif-1a
mutants are more sensitive to mechanical stimuli.27
In this study, we investigated the function of Hif-1a in
osteo-anabolic signaling by assessing the effect of Hif-1a
loss-of-function on bone formation in response to parathy-
roid hormone. In addition to hypoxia, Hif-1a expression is
induced by a number of stimuli and signaling pathways
critical for normal osteoblast function, including some
that are used by PTH to increase bone formation.27–29
Moreover, PTH stimulates vascular remodeling in bone,30
which suggests two potential mechanisms by which Hif-1
might impact PTH-induced anabolism. Here, we dem-
onstrate that PTH administration results in Hif-1a expression
by osteoblasts both in vivo and in vitro, and that by inter-
acting with b-catenin, Hif-1a suppresses the anabolic res-
ponse. As a result, the removal of Hif-1a from osteoblasts
and osteocytes sensitizes bone to PTH treatment by enhan-
cing the activity of osteoblasts. These findings indicate
that Hif-1a is a more general suppressor of osteo-anabolic
signaling and acts to inhibit signals beyond those asso-
ciated with mechanical loading.
MATERIALS AND METHODS
Generation of transgenic mice
The generation of mice lacking Hif-1a in osteoblasts and
osteocytes (DHif-1a) was described previously.26–27 Briefly,
OC-Cre mice31 were crossed with mice in which the sec-
ondexonofHif-1a is floxed.32MicecontainingHif-2a-floxed
alleles,33 Vhl-floxed alleles34 and mTOR-floxed (mTOR:
mammalian target of rapamycin) alleles35 have been
described previously. All mice were maintained on a
C57BL/6 background. PCRanalysis fromear or tail biopsies
was used to confirm genotypes. The Institutional Animal
Care and Use Committee of the Johns Hopkins University
School of Medicine approved all animal procedures.
Administration of human PTH in vivo
Female DHif-1a and control mice were grown until
10 weeks of age at which point daily (7 day per week)
subcutaneous injections of 100 mL vehicle or human PTH
1–34 (Bachem Inc., Torrance, CA, USA) were initiated. PTH
concentrations (20 mg?kg21 or 40 mg?kg21) were adjusted
weekly based on bodymassmeasurements. All micewere
sacrificed at 16 weeks of age. Blood samples were col-
lected at sacrifice for analysis of serum markers of bone
resorption and formation. Serumwas collectedand imme-
diately stored at 2806C. Serum concentrations of C-terminal
telopeptide (RatLaps; IDS Inc., Scottsdale, AZ, USA) and
N-terminal propeptide of type 1 procollagen (P1NP; IDS
Inc.) were determined via commercially available ELISA.
Two additional groups of female DHif-1a and control mice
were treated with PTH (40 mg?kg21 subcutaneous) for 4
or 16 h and then sacrificed. Femurs were dissected and
prepared for immunohistochemical analysis of Hif-1a
expression (sc-10790; Santa Cruz, Dallas, TX, USA) accord-
ing to standard techniques or homogenized in TRIzol
(Invitrogen, Grand Island, NY, USA) for RNA analysis after
flushing the bone of marrow.
Skeletal analysis
To examine bone architecture, the mouse femur was
scanned using a desktop microtomographic imaging sys-
tem (Skyscan 1172; Skyscan, Kontich, Belgium) in accord-
ance with the recommendations of the American Society
for Bone and Mineral Research.36 The femur was scanned
at 50 keV and 200 mA using a 0.5 mm aluminum filter
with an isotropic voxel size of 10 mm. The resulting two-
dimensional images are shown in gray scale. Trabecular
bone parameters were assessed in the distal femur 500 mm
proximal to the growth plate and extending for 2 mm (200
CT slices). Cortical bone parameters were assessed at the
femoral midshaft and represent an average of 50 CT slices
(500 mm). Dynamic measures of bone formation were
assessed by injection of two sequential 0.2 mL doses of
calcein (0.8 mg?mL21) delivered 3 and 10 days prior to
sacrifice. The femur was fixed in ethanol, dehydrated
andembedded inmethylmethacrylate. Threemicron sec-
tions were cut with a Micrommicrotome and stained with
Mason-Goldner trichrome stain. Thenumber of osteoblasts
and osteoclasts per bone perimeter were measured at
standardized sites under the growth plate at a magnifica-
tionof 3200usinga semi-automaticmethod (Osteoplan II;
Kontron, Munich, Germany). These parameters comply
with the guidelines of the nomenclature committee of
the American Society for Bone andMineral Research.37–38
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Osteoblast isolation and culture
Osteoblasts were isolated from the calvaria of newborn
Hif-1a-floxed, Hif-2a-floxed, mTOR-floxed and Vhl-floxed
mice by serial digestion in 1.8 mg?mL21 collagenase type
I and maintained in a-MEM (minimum essential medium,
alpha modification) supplemented with 10% FBS (Fetal
bovine serum) and 1% penicillin/streptomycin. To disrupt
Hif-1a, Hif-2a, mTOR or Vhl expression, osteoblasts were
infected with control adenovirus expressing green fluor-
escent protein or adenovirus expressingCre recombinase
(Vector Biolabs, Philadelphia, PA, USA) at anMOI (multipli-
city of infection) of 100. Osteoblasts were harvested 48 h
after adenoviral infection and deletion efficiency was
assessed in a portion of the cell population by real-time
PCR. The remaining cells were replated for stimulation
with PTH. Pharmacological agents were obtained from
Sigma Aldrich, dissolved in DMSO and added to cell cul-
tures with appropriate vehicle controls 30–60 min before
PTH treatments.
Quantitative real-time PCR and chromatin
immunoprecipitation
Total RNAwasextracted fromosteoblasts or homogenized
femurs using TRIzol (Invitrogen) and 1 mg was reverse tran-
scribed using the iScript cDNA synthesis system (Bio-Rad,
Hercules, CA, USA). Twomicroliters of cDNAwas subjected
to PCRamplification using the iQ SYBRGreen Supermix (Bio-
Rad). Primer sequences were obtained from PrimerBank
(http://pga.mgh.harvard.edu/primerbank/index.html).
Reactions were normalized to endogenous b-actin refer-
ence transcript.
Chromatin immunoprecipitation assays were per-
formed using an Agarose ChIP Kit (Pierce, Rockford, IL,
USA) according to the manufacturer’s instructions and a
ChIP-qualified antibody specific for b -catenin (PAS-16192;
Thermo Scientific, Waltham, MA, USA). Precipitated DNA
(2 mL) was subjected to PCR amplification by qPCR and
normalized to reference reactions utilizing input DNA.
Primer sequences for the Axin2 promoter are available
upon request.
Protein isolation and assays
Protein was extracted from cultured osteoblasts in 0.1%
Triton X-100 containing protease and phosphatase inhibi-
tors. The extracts were separated on 10% SDS/polyacryla-
mide gels and transferred to PVDF (polyvinyl difluoride)
membranes. Antibodies for Hif-1a (NB100–105), Hif-2a
(NB100–122) and Hif-1b (NB100–124) were obtained from
Novus Biological. Antibodies for phospho-Akt (S473, 9721),
Akt (9272), phospho-p70 S6 kinase (9206), p70 S6 kinase
(9202), phospho-Creb (9198), Creb (9197), phospho-Erk
(9101), Erk (9107) and b -catenin (2698) were obtained
from Cell Signaling Technologies, Danvers, MA, USA.
Bound antibodies were visualized using either the Super-
signal West Femto or West Pico Substrates (Pierce). Co-
immunoprecipitation was performed overnight at 46C in
a reaction containing 2 mg of antibody specific for Hif-1a
(Novus) or b-catenin (Cell Signaling Technologies, San
Diego, CA, USA).
Statistical analysis
Results are expressed as mean6s.e.m. All statistical tests
were two-sided. A P-value less than 0.05 was considered
significant. Comparability of two groups of data was
assessed using a Student’s t-test.
RESULTS
PTH stimulates Hif-1a expression in osteoblasts
Mice that lack Hif-1a in osteoblasts and osteocytes (Hif-
1aflox/flox; Oc-CreTG/1, hereafter referred to as DHif-1a)
exhibit early deficits in both cortical and trabecular bone
architecture that are at least partially attributable to
impairments in skeletal vascularization.25–26 As the mutant
mice mature, bone architecture normalizes,27 indicating
that Hif-1a exerts distinct developmental functions and
likely acts to suppress osteo-anabolic signaling. To assess
this inhibitory function,weexamined the influenceofHif-1a
on the response of osteoblasts to PTH.
To establish that Hif-1a regulates osteo-anabolic signal-
ing in response to PTH, we first examined the ability of
the hormone to induce the expression of Hif-1a in osteo-
blasts. In cultures of normoxic calvarial osteoblasts, PTH
(10 nmol?L21) rapidly increased Hif-1a protein levels, with
expression levels peaking between 2 and 4 h after stimu-
lation and remaining elevated through 8 h of treatment
(Figure 1a). Protein levels of Hif-2a and Hif-1b were not
affected. However, desferoxamine, an iron chelator that
inhibits the activity of the prolyl-hydroxylase enzymes that
initiate the targeting of Hif-a subunits for proteasomal
degradation, induced the expression of both Hif-1a and
Hif-2a (Figure 1b), indicating that the effects of PTH are
specific for Hif-1a. PTH administration also increased Hif-
1a expression in vivo as PTH treated mice (40 mg?kg21)
exhibited robust expression of Hif-1a in osteoblasts lining
trabecular bone surfaces, a subset of osteocytes, and
marrow components (Figure 1c), while saline treated ani-
mals exhibited only weak expression in these cell popula-
tions. Both in vitro (Figure 1d) and in vivo (Figure 1e), the
levels of Hif-1amRNA were unaffected by PTH stimulation,
suggesting that the induction of Hif-1aprotein occurs via a
post-transcriptional mechanism.
cAMP/protein kinase A (PKA) signaling induces Hif-1a
expression in response to PTH
PTH could increase Hif-1a protein levels without affecting
Hif-1a transcription by specifically enhancing Hif-1a trans-
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lation or by inhibiting proteasomal degradation. Since PTH
retained the capacity to increase Hif-1a protein levels in
osteoblasts deficient for Vhl (data not shown), we focused
on the induction of new Hif-1a synthesis. As expected, pre-
treatment of osteoblast cultures with cycloheximide, to
inhibit new protein synthesis, abolished the effect of PTH
on Hif-1a protein levels (Figure 2a and 2d). Moreover,
increases in the phosphorylation of Akt (S473) and p70 S6
kinase (Figure 2b) indicated that PTH activates mTOR, a
key regulator of Hif expression in response to anabolic sig-
nals.39–40 Adenoviral Cre-mediated disruption of mTOR
expression in osteoblasts containing mTORflox/flox alleles,
via an 83% reduction in mTOR mRNA levels, completely
inhibited the effect of PTH on Hif-1a protein (Figure 2c
and 2d).
We next explored the signaling mechanisms by which
PTH activates mTOR and ultimately increases Hif-1a pro-
tein. Because an increase in cellular cAMP signaling is a
primary response to PTH binding to its receptor,6,12 we ini-
tially assessed the effect of pharmacologically raising
cAMP levels on mTOR activity and Hif-1a expression.
Forskolin, which activates adenylyl cyclase, dose-depen-
dently stimulated the phosphorylation of Akt and p70 S6
kinase (Figure 2e and 2f), indicating that mTOR was
activated, and increased the levels of Hif-1a protein
(Figure 2gand2h). Toconfirm these results,wepre-treated
osteoblast cultures with H-89 to antagonize the activity of
PKA, the downstream mediator of cAMP signaling. This
approach greatly impaired the ability of PTH to stimulate
the phosphorylation of Akt and p70 S6 kinase (Figure 2i–
2k), even though baseline levels of p70 phosphorylation
were increased by H-89, and abolished the increase in
Hif-1aprotein (Figure 2l and2m). Together, thesedata sug-
gest a mechanism whereby PTH activates cAMP/PKA sig-
naling which in turn activates the mTOR pathway to
regulate Hif-1a expression.
DHif-1amice are more sensitive to anabolic PTH treatment
Todirectly assess theeffect of Hif-1aexpressionon theana-
bolic response of bone to PTH, we generated cohorts of
10-week-old female control and DHif-1a mice and admi-
nistered daily injections of PTH or saline, as a control, for
6 weeks. MicroCT analysis revealed equivalent trabecular
bone architecture in the distal femur of saline treated
control and DHif-1amice, which is consistent with our pre-
vious study27 that demonstrated a normalization of bone
volume in Hif-1a mutants (Figure 3a–d). PTH injections
(40 mg?kg21 BW, Body weight) produced the predicted
anabolic response and increased trabecular bone
volume by 155.41% in control mice (Figure 3a and 3b) by
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increasing trabecular number (Figure 3c) and thickness
(Figure 3d). In Hif-1amutants, PTH increased bone volume
an additional 22.86% relative to the treated control mice
(182.19% increase versus DHif-1a, saline-treated controls),
due to significantly larger increases in trabecular thickness
and slightly larger increases in trabecular number. PTH also
significantly increased cortical bone thickness, but the
effect was indistinguishable between control and Hif-1a
mutantmice (data not shown). Likewise, increases in body
weight were equivalent among control and Hif-1amutant
mice (data not shown). When we reduced the daily dose
of PTH to 20 mg?kg21, the increase in trabecular bone
volume in the mutant mice (182.79% increase versus DHif-
1a, saline-treated controls) was identical to that of the
40 mg?kg21 treatment group, while the percent increase
in the control mice was reduced by 29.91% (Figure 3a
and 3b). Taken together, these data suggest that disrupting
the expression of Hif-1a increases the sensitivity of bone to
intermittent PTH.
To understand the cellular basis for the enhanced ana-
bolic response in DHif-1a mice, we performed dynamic
histomorphometric and serological analyses of bone
formation. Since all measures were equivalent in the
saline-treated control and DHif-1a mice, results are pre-
sented as the relative increase above this baseline level
(Figure 3e–3i). PTH increased the mineralizing surface per
bone surface toa similar extent in control andDHif-1amice
(Figure 3e), but the mutant mice exhibited a 23.2%
increase in mineral apposition rate while no effect of PTH
on this parameter was observed in the control mice
(Figure 3f). This led to a greater overall increase in bone
formation rate in the mutant mice relative to the control
mice (Figure 3g). Similarly, serum levels of P1NP (Figure 3h),
a marker of bone formation, were increased to a greater
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Hif-1a suppresses PTH action
JL Frey et al
5
 2014 Sichuan University Bone Research (2014) 14005
extent in the mutant mice relative to controls, while the
levels of C-terminal telopeptide (Figure 3i), a marker of
bone resorption, were increased to a similar degree.
Thus, the amplified sensitivity of Hif-1amutant mice to PTH
and augmented bone formation response appear to be
due to an increase in the functional activity of individual
osteoblasts.
Hif-1a antagonizes the actions of b-catenin after PTH
stimulation
Finally, we assessed cellular signaling mechanisms that
might account for the increased responsiveness of Hif-1a
mutant mice to PTH. Calvarial osteoblasts were isolated
from Hif-1aflox/flox mice and infected with adenoviral con-
structs expressing Cre to eliminate Hif-1a expression
(Figure 4a) or green fluorescent protein as a control. We
next examined the effect of eliminating Hif-1a expression
on the activation of the primary PTH-responsive pathways,
but the increase in cellular cAMP levels (Figure 4b) and the
phosphorylation of Creb and Erk (Figure 4c) were similar in
control and Hif-1a deficient osteoblasts. By contrast, the
increase in Axin2 and Nkd2 mRNA levels was enhanced
after PTH treatment in DHif-1a osteoblasts relative to
those of controls (Figure 4d and 4e), suggesting that the
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Hif-1a mutant (DHif-1a) mice were treated with vehicle or PTH for 6 weeks by daily s.c. injection. (a) Representative microCT images illustrate
trabecular bone structure in the distal femur of control andDHif-1amice after treatmentwith PTH at the indicated doses. (b–d) Bone volume per tissue
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activation of b-catenin was increased.41 To test the spe-
cificity of this apparent inhibitory effect of Hif-1aon b-cate-
nin activity, we overexpressed Hif-1a by eliminating the
expression of Vhl (Figure 4f), and as expected this genetic
manipulation impaired the ability of PTH to increase the
expression of Axin2 (Figure 4g). The expression of Hif-1a in
response to PTH did not alter the accumulation or nuclear
localization of b-catenin (Figure 4h), but rather Hif-1a
directly interacted with b-catenin (Figure 4i) and acted
to inhibit the binding of b-catenin to the promoter of target
genes (Figure 4j). We observed a similar effect in vivoas PTH
produced a significant increase in Axin2 mRNA levels in the
femurs of DHif-1amice, but not those of control mice. These
data imply that the enhanced bone formation response
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evident in Hif-1amutant mice stems from the elimination of
Hif-1a-mediated suppression of b-catenin signaling.
DISCUSSION
In this study, we demonstrate that the transcription factor
Hif-1a acts to suppress the anabolic actions of parathyroid
hormone. Hif-1a protein levels were rapidly upregulated
both in vitro and in vivo by PTH stimulation and mice ren-
dered deficient for Hif-1a in osteoblasts and osteocytes
were more responsive to intermittent administration of
the hormone. Themore dramatic increase in bone forma-
tionevident inHif-1amutantmiceappears to result froman
increase in the performance of individual osteoblasts sec-
ondary to an enhancement of b-catenin target gene
expression.
In addition to hypoxia, Hif-1a is induced by a number
of anabolic signals relevant to bone metabolism.
Mechanical loading,42 growth factors and paracrine
factors like prostaglandins43–45 all increase Hif-1a protein
levels. Some of these factors have also been implicated
in the anabolic response of bone to PTH. Insulin-like growth
factor-1, for instance, induces Hif-1a expression,46 and
removal of its receptor diminishes bone formation in res-
ponse to the hormone.13 While insulin-like growth factor-1
might partially contribute to the induction of Hif-1a after
PTH stimulation, the rapid effect we observed suggests
a more direct effect on Hif-1a synthesis. Indeed, our
data suggest that PTH activates cAMP/PKA signaling to
increase the activity of mTOR, which can directly regulate
Hif-1a translation.39–40,47 While not directly examined here,
studies in other tissues indicate that PKA can activate
mTOR signaling via a number of mechanisms, including
the engagement of PI3K/Akt signaling and the phosphor-
ylation of TOR complex components.48–49
As alluded to above, mTOR signaling has also been
demonstrated to bean important component of the ana-
bolic response of bone to PTH, as rapamycin treatment
inhibits the increase in trabecular bone volume resulting
from high-dose PTH administration by reducing osteoblas-
tic activity.29 In light of our data, it would appear that
mTOR plays a dual role in the response of bone to intermit-
tent PTH, facilitating anabolism while also establishing a
mechanism to suppress anabolic signaling via induction
of Hif-1a expression. We focused our analysis on the
effects of Hif-1a on b-catenin signaling because of its
well-documented anabolic role in the skeleton, but we
cannot rule out the possibility that Hif-1a also regulates
the expression of factors that inhibit mTOR signaling.50
Even thoughangiogenesis is awell-explored response to
increased Hif-1a signaling and PTH has been shown to
induce skeletal vascular remodeling,30 it does not appear
that this effect factors into the anabolic response we
observed. If vascular remodeling and the relocalization
of blood vessels to sites of new bone formation were regu-
lated by Hif-1a, we would have expected the disruption of
Hif-1a expression to impair the osteo-anabolic response.
However, we cannot completely rule out a compensatory
effect of the closely related Hif-2a. Rather, as we have
suggested previously,27 it is likely that Hif-1a assumes an
inhibitory role in themature skeleton toprevent unchecked
anabolic signaling and the generation of signals that
impinge on cellular function. Hif-1a is induced by reactive
oxygen species, and Hif-1-generated signals in turn reduce
new oxidant production.51–54 Therefore, induction of Hif-1a
may ensure cellular longevity and facilitate cellular repair
after the generation of cellular stressors during an anabolic
response.
The results presented here are consistent with our pre-
vious finding that Hif-1a acts to inhibit the anabolic res-
ponse to a tibia-loading regime and potentially does so
by suppressing b-catenin activity.27 However, several
important differences exist when the cellular basis of each
response is considered. Our mechanical loading study
demonstrated that Hif-1a inhibited the anabolic response
in the cortical bone envelope, but in these studies, PTH
produced similar increases in cortical bone thickness in
control and mutant mice. Likewise, the number of osteo-
blasts activated by mechanical loading was greatly
increased in Hif-1a mutant mice, but the effect of PTH on
bone formation in these mice appears to be related to
a larger increase in the functional output of individual
osteoblasts. Here, the mineralizing surface was similarly
enhanced in control and mutant mice, but the mineral
apposition rate and P1NP levels were enhanced by the
genetic removal of Hif-1a. While we cannot exclude the
possibility that thedifferential effectsare simply the result of
different bone compartments, these data suggest that
the suppressive actions of Hif-1a may be dependent on
the cellular context and the stimulus.
Nonetheless, the significant increase in the anabolic
effect of each of these stimuli suggests that Hif-1a activity
could be targeted in therapeutic paradigms. Previous
studies have identified pharmacological molecules that
impair Hif-1a transcriptional activity or interaction with
binding partners.55–57 While these studies have primarily
focused on the prevention of tumor growth and tumor-
induced angiogenesis, these agents or molecules with
similar functions could be adapted to enhance anabolic
therapies in bone. After prolonged treatment with inter-
mittent PTH, markers of bone formation begin to decline,
suggestive of the development of a resistance to the
anabolic effects of the therapy.58–59 Whether increased
expression of Hif-1a contributes to this effect will require
additional studies. However, our studies suggest that an
agent that inhibits the expression of Hif-1a or impairs the
interaction of Hif-1a and b-catenin could be used to lower
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the therapeutic dose of PTH necessary to decrease frac-
ture risk or increase the anabolic response.
In summary, our studies support a role for Hif-1a as a
negative regulator of osteo-anabolic signaling. In early
development, Hif-1a functions in bone cells to facilitate
the vascularization of long bones, a process that is required
for normal bone acquisition. As bone matures, Hif-1a
assumes a new function that likely acts to restrain osteo-
blast and osteocyte activity and does so by interferingwith
a key component of the Wnt signaling pathway. Our stud-
ies provide a broader understanding of the molecular
physiology of Hif-1a in bone cells and may lead to the
design of strategies to augment skeletal therapeutics.
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